Williams Jones & Associates’s REGENERX BIOPHARMACEUTICALS RGN Stock Holding History

Williams Jones & Associates’s Portfolio RGN Stock Details RGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	$25K	Sell	140,000 -10,000	-7%	-$1.79K	﹤0.01%	391
2019 Q1	$35K	Hold	150,000	–	–	﹤0.01%	406
2018 Q4	$23K	Hold	150,000	–	–	﹤0.01%	389
2018 Q3	$27K	Hold	150,000	–	–	﹤0.01%	441
2018 Q2	$30K	Hold	150,000	–	–	﹤0.01%	438
2018 Q1	$33K	Hold	150,000	–	–	﹤0.01%	441
2017 Q4	$26K	Hold	150,000	–	–	﹤0.01%	435
2017 Q3	$50K	Buy	150,000 +40,000	+36%	+$13.3K	﹤0.01%	426
2017 Q2	$30K	Hold	110,000	–	–	﹤0.01%	408
2017 Q1	$32K	Hold	110,000	–	–	﹤0.01%	402
2016 Q4	$35K	Hold	110,000	–	–	﹤0.01%	373
2016 Q3	$41K	Hold	110,000	–	–	﹤0.01%	393
2016 Q2	$51K	Buy	+110,000	New	+$51K	﹤0.01%	380

Other funds holding RGN

DBIA

Dumont & Blake Investment Advisors Princeton, New Jersey $400M AUM 21.87% 1-Year Est. Return

Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return

Williams Jones & Associates's RGN Position: Q2 2019 in Review

Williams Jones & Associates reduced its REGENERX BIOPHARMACEUTICALS (RGN) stake by 6.7% in Q2 2019, selling an estimated $1.79K and leaving 140,000 shares worth $25K. The position accounts for ﹤0.01% of the portfolio, ranked #391.

Williams Jones & Associates first reported a position in RGN in Q2 2016 and has held it in 13 quarters since. The position peaked at $51K in Q2 2016. 3 funds tracked by Wall St. Rank hold RGN as of Q2 2019.

Williams Jones & Associates held 140,000 shares of REGENERX BIOPHARMACEUTICALS worth $25K as of Q2 2019.
Williams Jones & Associates sold 10,000 REGENERX BIOPHARMACEUTICALS shares in Q2 2019, an estimated $1.79K.
REGENERX BIOPHARMACEUTICALS made up ﹤0.01% of Williams Jones & Associates's portfolio in Q2 2019, its #391 holding.
Williams Jones & Associates first reported a position in REGENERX BIOPHARMACEUTICALS in Q2 2016 and has held it in 13 quarters since.
Williams Jones & Associates's REGENERX BIOPHARMACEUTICALS position peaked at $51K in Q2 2016.
3 funds tracked by Wall St. Rank held REGENERX BIOPHARMACEUTICALS as of Q2 2019.

Based on Williams Jones & Associates's 13F filing for Q2 2019, filed 14 Aug 2019.